Takeda, Lilly lose bid to overturn $9 bln award for hiding cancer risk | Business Information & News | Westlaw

Takeda, Lilly lose bid to overturn $9 bln award for hiding cancer risk | Business Information & News | Westlaw

View on Westlaw or start a FREE TRIAL today, Takeda, Lilly lose bid to overturn $9 bln award for hiding cancer risk, Business Information & News
9/2/14 REUTERS 11:17:31
REUTERS
Copyright © 2014 Thomson Reuters
September 2, 2014
Takeda, Lilly lose bid to overturn $9 bln award for hiding cancer risk
Anjali Rao Koppala
Chang-Ran Kim
(Reuters) - Takeda Pharmaceutical Co Ltd and Eli Lilly & Co lost a bid to overturn a combined $9 billion punitive damage award by a U.S. jury for hiding cancer risks associated with their Actos diabetes drug, according to a court ruling.
"Plaintiffs...
---- Index References ----
Company: TAKEDA PHARMACEUTICAL CO LTD
News Subject: (General Interest Diabetes (1GE92); Legal (1LE33); Major Corporations (1MA93); Judicial Cases & Rulings (1JU36); Health & Family (1HE30))
Industry: (Pharmaceuticals & Biotechnology (1PH13); Pharmaceuticals (1PH33))
Region: (Japan (1JA96); Eastern Asia (1EA61); Far East (1FA27); Asia (1AS61))
Language: EN
Other Indexing: (Eli Lilly & Co) (Rebecca Doherty)
Keywords: health; products (MCC:f); (N2:US); (N2:AMERS); (N2:USA); (MCCL:OVR)
Word Count: 395
End of Document© 2024 Thomson Reuters. No claim to original U.S. Government Works.